Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

Delray Medical Center cut the ribbon on its newest high-tech machine that targets brain areas to treat movement disorders ...

The Florey Dementia Index (FDI) is valid for predicting the age of onset of mild cognitive impairment (MCI) and Alzhei ...

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

IGC Pharma, Inc (NYSE American:IGC) (”IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi ...

Having depression is known to increase a person’s risk of developing dementia, but depression is also an early indicator of ...

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by ...

Mild chronic small vessel disease, or cerebral small vessel disease (CSVD), is an umbrella term for a range of conditions ...

The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

Gum disease appears to disrupt brain activity, potentially increasing a person’s risk of cognitive decline.People with ...

Knowing the warning signs of dementia is important for dealing with the debilitating condition that currently has no cure.

Preserving levels of brain glucose metabolism can both slow cognitive decline and reduces the risk of conversion to dementia.